OSCR
Oscar Health, Inc.
OSCR has the edge over TAK overall, supported by stronger fundamentals and stronger modeled upside.
TAK
Takeda Pharmaceutical Company Limited
TAK has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TAK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Under pressure |
TAK's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
TAK PE Valuation
TAK has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over TAK on the outlook, with more favorable revenue expectations.
TAK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect TAK's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 147% for OSCR versus TAK up 83%.
TAK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.35 | +30% |
| Q2 2025 | $0.27 | -6.9% |
| Q1 2025 | $0.21 | -28% |
| Q4 2024 | $0.41 | +17% |
| Q3 2024 | $0.57 | +50% |
| Q2 2024 | $0.29 | -52% |
| Q1 2024 | $0.29 | -54% |
| Q4 2023 | $0.35 | -36% |
TAK earned $0.75 per share over the past year, up 83% from the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over TAK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
TAK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.4B | +6.7% |
| Q2 2026 | $7.6B | +10% |
| Q1 2026 | $7B | +5.8% |
| Q4 2025 | $7.6B | +6% |
| Q3 2025 | $7B | -5.4% |
| Q2 2025 | $6.9B | -8.4% |
| Q1 2025 | $6.6B | +0.2% |
| Q4 2024 | $7.2B | +3% |
TAK's revenue has grown year over year for four quarters in a row: $7.4B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 17% | +11 points |
| Q2 2026 | 17% | N/A |
| Q1 2026 | 4.3% | -12 points |
| Q4 2025 | 16% | +23 points |
| Q3 2025 | 6.2% | +0.4 points |
| Q2 2025 | 17% | +2.9 points |
| Q1 2025 | -7.1% | -6.2 points |
| Q4 2024 | 5.8% | -3.6 points |
TAK has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over TAK on cash flow, with more consistent year-over-year improvement.
TAK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $462.7M | -47% |
| Q1 2026 | $63.5M | -92% |
| Q4 2025 | $945.7M | -54% |
| Q3 2025 | $2B | +73% |
| Q2 2025 | $879.7M | +735% |
| Q2 2025 | $879.7M | +735% |
| Q1 2025 | $811.3M | -40% |
| Q4 2024 | $2.1B | +372% |
TAK still generates free cash flow, though less than at its 2022 peak: $3.5B over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TAK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +1.7% | +54.5M shares |
| 3 years | +2.5% | +78.8M shares |
| 5 years | +1.5% | +48.6M shares |
| Available history | +3% | +94M shares |
TAK has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $6.3M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $323.4M |
| Q1 2025 | $313.3M |
| Q4 2024 | — |
| Q3 2024 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over TAK on leverage, with a lower net debt burden relative to earnings.
TAK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.1x | Elevated |
| Q2 2026 | 3.5x | Elevated |
| Q2 2025 | 3.5x | Elevated |
| Q1 2025 | 3.6x | Elevated |
| Q4 2024 | 3.6x | Elevated |
| Q3 2024 | 3.3x | Elevated |
| Q2 2024 | 4.2x | High |
| Q1 2024 | 4.0x | High |
TAK's net debt is about 3.1 years of its operating earnings (EBITDA), down from 3.6 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TAK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.9 | Overbought |
| Stochastic | 89.0 | Overbought |
TAK's weekly RSI is 74 (overbought) and its Stochastic is 89 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TAK PE vs Healthcare Sector
| Metric | TAK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TAK has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
TAK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.8 | 6.7% above |
| 20 week MA | $18.5 | 14% above |
| 50 week MA | $17.4 | 21% above |
| 100 week MA | $15.9 | 33% above |
| 200 week MA | $15.3 | 38% above |
TAK is in an uptrend: it's above all five of its weekly moving averages, and 38% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over TAK on returns for 2026, with the stronger performance.
TAK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.8 | $18.1 | -8.7% |
| 2021 | $18.1 | $13.8 | -24% |
| 2022 | $13.8 | $15.5 | +13% |
| 2023 | $15.5 | $14.3 | -8.2% |
| 2024 | $14.3 | $13.3 | -7% |
| 2025 | $13.3 | $15.7 | +18% |
| 2026 YTD | $15.7 | $21.1 | +35% |
TAK is up 35% so far in 2026, after finishing lower in four of the previous six years.